NO924372L - Anordning for kontrollert avgivelse - Google Patents

Anordning for kontrollert avgivelse

Info

Publication number
NO924372L
NO924372L NO92924372A NO924372A NO924372L NO 924372 L NO924372 L NO 924372L NO 92924372 A NO92924372 A NO 92924372A NO 924372 A NO924372 A NO 924372A NO 924372 L NO924372 L NO 924372L
Authority
NO
Norway
Prior art keywords
active substance
core
reading
exposed
fluid medium
Prior art date
Application number
NO92924372A
Other languages
English (en)
Other versions
NO924372D0 (no
Inventor
Sham Kumar Chopra
Avinash Kumar Nangia
David Lee
Thomas Patrick Molloy
Original Assignee
Glaxo Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919124108A external-priority patent/GB9124108D0/en
Priority claimed from GB919124106A external-priority patent/GB9124106D0/en
Priority claimed from GB929205463A external-priority patent/GB9205463D0/en
Application filed by Glaxo Canada filed Critical Glaxo Canada
Publication of NO924372D0 publication Critical patent/NO924372D0/no
Publication of NO924372L publication Critical patent/NO924372L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molding Of Porous Articles (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Container, Conveyance, Adherence, Positioning, Of Wafer (AREA)
  • Seal Device For Vehicle (AREA)

Abstract

Denne oppfinnelse vedrører en anordning for avgivelse av minst en aktiv substans (f.eks. ranitidin) til et fluid medium ved opplesning, omfattende et belegg som er ugjennomtrengelig for den aktive substans og fluidet, som har minst en åpning deri og som definerer et dannet hulrom, og at hulrommet er fylt med en formet kjerne omfattende den aktive substans, og hvori: a) en overflate av kjernen blir eksponert ved eksponering av anordningen for det fluide medium, og opplesning av overflaten ved det fluide medium forårsaker en forandring i minst en dimensjon av overflatearealet, mens overflatearealet av den eksponerte overflate holder seg i alt vesentlig konstant over minst 50% av den samlede opplesningstid for kjernen; eller b) den aktive substans er fordelt i en matriks av en inert uleselig eksipient, anordningen er aksielt symmetrisk med sin åpning plassert i periferien slik at kjernens avgivelses- overflate som eksponeres gjennom åpningen er i alt vesentlig sylindrisk eller del av en sylinder i form, hvorved det tilla- tes i alt vesentlig konstant avgivelse av den aktive substans over minst en del av opplesningstiden; og fremgangsmåter for dens fremstilling.
NO92924372A 1991-11-13 1992-11-12 Anordning for kontrollert avgivelse NO924372L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919124108A GB9124108D0 (en) 1991-11-13 1991-11-13 Device
GB919124106A GB9124106D0 (en) 1991-11-13 1991-11-13 Device
GB929205463A GB9205463D0 (en) 1992-03-12 1992-03-12 Device

Publications (2)

Publication Number Publication Date
NO924372D0 NO924372D0 (no) 1992-11-12
NO924372L true NO924372L (no) 1993-05-14

Family

ID=27265924

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924372A NO924372L (no) 1991-11-13 1992-11-12 Anordning for kontrollert avgivelse

Country Status (15)

Country Link
US (1) US5342627A (no)
EP (1) EP0542364B1 (no)
JP (2) JP3768247B2 (no)
AT (1) ATE133331T1 (no)
AU (1) AU658942B2 (no)
CA (1) CA2082740C (no)
CZ (1) CZ337392A3 (no)
DE (1) DE69207863T2 (no)
DK (1) DK0542364T3 (no)
ES (1) ES2083074T3 (no)
GR (1) GR3019431T3 (no)
IL (1) IL103723A0 (no)
NO (1) NO924372L (no)
NZ (1) NZ245100A (no)
TW (1) TW262387B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5398850A (en) 1993-08-06 1995-03-21 River Medical, Inc. Gas delivery apparatus for infusion
DE4341442C2 (de) * 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
DE4431653C2 (de) 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US5700245A (en) 1995-07-13 1997-12-23 Winfield Medical Apparatus for the generation of gas pressure for controlled fluid delivery
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US6110500A (en) * 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
EP1095650A1 (en) * 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system
US6569152B2 (en) 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
MXPA03005339A (es) * 2000-12-14 2004-03-26 Johnson & Johnson Productos de hormona esteroide que comprenden un agente de estabilizacion en forma no cristalina.
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
AU2002359407B2 (en) 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1703197A (zh) * 2001-11-14 2005-11-30 阿尔扎有限公司 可注射的长效组合物和其使用
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
PT1524981E (pt) * 2002-07-29 2009-06-17 Glaxo Group Ltd Formulações de libertação controlada contendo lamotrigina
MXPA05001242A (es) * 2002-07-31 2005-06-08 Alza Corp Composiciones de deposito inyectable y usos de las mismas.
EP1539101B1 (en) * 2002-07-31 2009-01-07 ALZA Corporation Injectable multimodal polymer depot compositions and uses thereof
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1970055B1 (en) * 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
AU2009281537A1 (en) * 2008-08-14 2011-06-30 Bioneer A/S Coated tablets with a remaining degradation surface over the time
WO2010096820A1 (en) * 2009-02-23 2010-08-26 Eurand, Inc. Controlled release compositions comprising anti-cholinergic drugs
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
WO2012080833A2 (en) * 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
WO2015160595A1 (en) * 2014-04-14 2015-10-22 Abbott Molecular, Inc. Medium used for blood sample collection and transport
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US480076A (en) * 1892-08-02 Thomas p
US3113076A (en) * 1956-07-03 1963-12-03 Henry R Jacobs Medicinal tablets
GB1022171A (en) * 1961-06-15 1966-03-09 Wellcome Found Prolonged release oral pharmaceutical tablets and their manufacture
US3851648A (en) * 1973-10-11 1974-12-03 Mead Johnson & Co Zero-order release device
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance

Also Published As

Publication number Publication date
JP4166716B2 (ja) 2008-10-15
AU658942B2 (en) 1995-05-04
EP0542364A1 (en) 1993-05-19
ATE133331T1 (de) 1996-02-15
ES2083074T3 (es) 1996-04-01
JP2004189754A (ja) 2004-07-08
DK0542364T3 (da) 1996-03-11
CA2082740A1 (en) 1993-05-14
TW262387B (no) 1995-11-11
JPH05262640A (ja) 1993-10-12
US5342627A (en) 1994-08-30
JP3768247B2 (ja) 2006-04-19
IL103723A0 (en) 1993-04-04
CA2082740C (en) 2003-10-14
DE69207863D1 (de) 1996-03-07
NZ245100A (en) 1995-06-27
EP0542364B1 (en) 1996-01-24
AU2827292A (en) 1993-05-20
DE69207863T2 (de) 1996-06-05
NO924372D0 (no) 1992-11-12
GR3019431T3 (en) 1996-06-30
CZ337392A3 (en) 1993-10-13

Similar Documents

Publication Publication Date Title
NO924372L (no) Anordning for kontrollert avgivelse
Murphy et al. William James on psychical research.
YU46983B (sh) Transdermalni sistem koji deluje preko kože
GB977375A (en) Applicator in combination with a pressurized aerosol container
NO801871L (no) Sprederanordning.
GOLDFISCHER et al. Peroxidase activity in peroxisomes (microbodies) of acatalasemic mice
FR75719E (fr) Valve de purge pour le desserrage des freins automatiques à fluide sous pression
FR1577690A (no)
Suzue et al. Carotenogenesis and resistance of Micrococcus pyogenes to tetracyclines
UY23323A1 (es) Procedimiento para la preparacion de una premezcla de semduramicina
MY106930A (en) Controlled release device
Mori et al. Differential responses of endogenous adult mouse neural precursors to excess neuronal excitation
DK0521353T3 (da) Lægemiddel med antineoplastisk virkning, der som virksomt stof indeholder octadecyl-(2-(N-metylpiperidino)-ethyl)-phosphat og fremgangsmåde til fremstilling deraf
FR1292097A (fr) Dispositif de commande des freins à mâchoires à l'aide d'un fluide sous pression
Faust Parasiticidal Potencies of the Tri-to Hepta-Methyl Derivatives of Rosanilin.
DK316783D0 (da) Spasmolytisk aktiv (+)-s-enantiomer af secoverin, fremgangsmade til dens fremstilling samt dens anvendelse
PERSAUD et al. Inhibition of insulin release by staurosporine and Ro 31–8220: a role for protein kinase C?
Holder et al. The effect of rations on vitelline membrane strength
FR1195299A (fr) Dispositif de freinage à fluide sous pression commandé électriquement
FR1188143A (fr) Dispositif permettant de régler les efforts produits par un appareil à commande par fluide sous pression, en fonction des déplacements d'un organe de machine
FR1115589A (fr) Distributeur pour fluide sous pression et ses applications, en particulier à la commande d'embrayages
BE595531R (fr) Valve de purge pour le desserrage des freins automatiques à fluide sous pression
ZAMAIMURADOVA SOME DATA ON ZOOPLANKTON OF RESERVOIRS IN THE MARY AND CHARDZHOU REGIONS OF THE TURKMEN SSR,(IN RUSSIAN)
ES2109147B1 (es) Composicion insecticida.
DYE et al. CATION FLUX ACROSS BIOMEMBRANES